Is NCT07140679 recruiting in Atlanta, GA?

Yes, NCT07140679 is currently recruiting participants at its Atlanta, GA location. This colon cancer clinical trial is actively enrolling qualified participants.

How do I join the colon cancer clinical trial in Atlanta?

To join this clinical trial in Atlanta, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Atlanta clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Colon Cancer Clinical Trial in Atlanta, GA

Who Can Participate

Inclusion Criteria

Patients with resected pathologic stage IIB, IIC and III dMMR colon cancer (American Joint Committee on Cancer \[AJCC\] 8)

Deficient mismatch repair (MMR) by immunohistochemistry or microsatellite instability (MSI-H) by polymerase chain reaction (PCR) or next generation sequencing (NGS)

Complete (R0) resection of pathologic stage IIB, IIC and III dMMR colon cancer 4 to 12 weeks prior to first dose of study drug

Available tissue sample from surgical specimen

Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Absolute neutrophil count (ANC) ≥ 1,500 /mcL

Platelets ≥ 100,000 / mcL

Hemoglobin ≥ 9 g/dL or ≥ 5.0 mmol/L

Transfusion is allowed to obtain an adequate hemoglobin level

Creatinine ≤ 1.5 x upper limit of normal (ULN) or measured or calculated creatinine clearance ≥ 40 mL/min for patient with creatinine levels \> 1.5 x institutional ULN (glomerular filtration rate \[GFR\] can also be used in place of creatinine or creatinine clearance \[CrCl\])

Creatinine clearance should be calculated per institutional standard

Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5 x ULN

Patients with previously diagnosed Gilbert syndrome can have total bilirubin \< 3.0 mg/dL

Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) ≤ 2.5 x ULN

Alkaline phosphatase ≤ 2.5 x ULN

Signed informed consent

Patients at least 18 years of age

Must have had a full colonoscopy prior to enrollment. If synchronous colon cancers are present, both must have deficient MMR and both must have undergone complete resection for patient to be eligible

Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP are women younger than 55 years (yrs) of age excluding those who are surgically unable to get pregnant due to prior hysterectomy and or bilateral salpingo-oophorectomy

Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 90 days after the last dose of study drug. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard

Female patients who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 90 days after the last dose of study drug

Exclusion Criteria

Neoadjuvant treatment for dMMR colon cancer

Presence of metastatic dMMR colon cancer

Underlying medical conditions that, in the investigator's opinion, will make the administration of the study drug hazardous or obscure the interpretation of adverse events

Uncontrolled psychiatric illness or psychological condition potentially hampering compliance with the study protocol and follow-up schedule

History of pneumonitis requiring treatment with steroids, or history of interstitial lung disease

History of a hematologic or primary solid tumor malignancy within the last 5 years

Autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo, diabetes mellitus type 1, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, controlled psoriasis or resolved childhood asthma/atopy not requiring systemic treatment can be enrolled

Active hepatitis B or hepatitis C

Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment

Treatment with live vaccines within 30 days prior to the first dose of study medication. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, nasal seasonal flu, H1N1 flu, rabies, Bacille Calmette Guerin (BCG) and typhoid vaccine

Prior treatment with any immune checkpoint inhibitor

Current pregnancy or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT07140679) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colon Cancer Treatment Options in Atlanta, GA

If you're searching for colon cancer treatment options in Atlanta, GA, this clinical trial (NCT07140679) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced colon cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colon cancer clinical trials near you to find additional studies recruiting in your area.

Colon Cancer Clinical Trial in Atlanta, GA

Expert Care in Atlanta

IRB Approved

No-Cost Care

Apply for This Atlanta Location

Why Participate?

Simple Process

About This Colon Cancer Study in Atlanta